EarlySight aims to reduce vision loss.
“As the RPE plays an important role in many retinal diseases, assessing the microstructure on a cellular level looks very promising. With upcoming drugs, at present in phase 3 trials, for dry AMD, we are possibly on the border of an new age in ophthalmology where dry AMD can be treated. A detailed assessment of the RPE will be crucial for monitoring treatment”
“This looks very interesting and is new compared to what is known from a research point of view”
“It is an improvement in technology and is attractive for research hospitals”
Brands: Our technology is the first to provide non-invasive images of the retinal pigment epithelium cells in human in only few seconds.